The former CEO of Valeant Pharmaceuticals has been ordered to submit to binding arbitration his dispute with the company over allegedly unpaid stock options.

J. Michael Pearson, who left the company after eight years in May 2016, claimed in a suit that the arbitration clause in his 2015 employment agreement was superseded by terms of his separation agreement, which did not require arbitration.

But U.S. District Judge Brian Martinotti ruled Wednesday that an arbitration provision in a prior agreement is superseded by a later agreement without an arbitration provision only if the subsequent agreement contains “an unambiguous complete integration or merger clause.”

Pearson says in his suit that the company made good on its promise to pay him a $9 million severance payment and some other terms. Valeant also provided and indicated that it will continue to provide him with health insurance coverage, office space, an administrative assistant and IT support, according to Pearson. But the company failed to honor its obligation to deliver his vested shares of company stock, which were due to him in November 2016, Pearson asserts in his suit. He says the company owes him over 3 million company shares, which have a value of $64 million based on Friday's stock price of $21.28 per share. His suit also says he is owed a $180,000 consulting fee.

Pearson said the company recently “has made an abrupt decision simply to stop honoring its full obligations, without even attempting to articulate any legal or factual basis for its sudden change of course.”

According to Pearson's suit, Valeant General Counsel Christina Ackermann told him “the board has reviewed the matter and determined that the shares will not be released to Mike Pearson due to the circumstances that Valeant finds itself in at this time.”

And another, unidentified attorney for Valeant told Pearson in a letter, “Valeant believes it would be inappropriate or inequitable in the current environment for Mr. Pearson to receive additional compensation—to the tune of millions of dollars—at a time when countless other Valeant employees have been asked to sacrifice for the good of the company and its shareholders.”

Pearson's separation agreement does not completely supersede his employment agreement, but merely “supersedes any other written or oral promises concerning the subject matter of the separation agreement,” Martinotti said. The subject matter of the 2015 arbitration agreement is different from that of the separation agreement, he said. Arbitration is beyond the subject matter of the separation agreement, and the arbitration provision of the 2015 employment agreement survives, Martinotti said.

Pearson cited several cases where separation agreements were found to have completely superseded employment agreements, but those cases were not applicable because the separation agreements in question contained language stating explicitly that they completely superseded the employment agreements, Martinotti said.

“There is no clear and convincing evidence that the parties chose to seek relief in a different forum. A review of the separation agreement clearly demonstrates it only intended to supersede 'any other written or oral promises concerning the subject matter of this Agreement,'” Martinotti said.

“The parties unambiguously contracted to save the arbitration clause when they decided not to draft a complete merger clause. The parties chose to include the limiting phrase 'concerning the subject matter of this Agreement,' and the Court cannot and will not ignore it,” Martinotti said.

Pearson departed as Valeant, a Canadian company with U.S. headquarters in Bridgewater, New Jersey, became the focus of investigations by Congress, U.S. attorneys in Massachusetts and New York, and the U.S. Securities and Exchange Commission, which have damaged the company's share price, according to the New York Times. Under Pearson, the company was drawn into controversies for its practice of acquiring drugs from other companies and sharply increasing their prices.

Jyotin Hamid of Debevoise & Plimpton in New York, representing Pearson, declined to comment on the ruling. Pearson is also represented by Blank Rome in Princeton, New Jersey.

The lawyers for Valeant, John Bennett of Jackson Lewis in Morristown, New Jersey, and Paul Spagnoletti and Andrew Ditchfield of Davis Polk & Wardwell in New York, did not return calls about the case.